|
|
 |
| |
|
Home > Drug Companies > Somerset Pharmaceuticals, Inc.
| |
Pharmaceutical Courses |
|
Pharmacy Technician
Allied College
Arnold, MO |
Pharmacy Technician
Allied College
Saint Ann, MO |
Pharmacy Technician
Cambridge College
Portland, OR |
Pharmacy Technician
Cambridge College
Seattle, WA |
Pharmacy Technician
High Tech Institute
Irving, TX |
Pharmacy Technician
High Tech Institute
Atlanta, GA |
Pharmacy Technician
High Tech Institute
Memphis, TN |
Pharmacy Technician
High Tech Institute
Minneapolis, MN |
Pharmacy Technician
High Tech Institute
Orlando, FL |
Pharmacy Technician
High Tech Institute
Sacramento, CA |
Pharmacy Technician
The Bryman School
Phoenix, AZ |
|
Somerset Pharmaceuticals, Inc.
Somerset Pharmaceuticals is a proprietary research and development pharmaceutical company located in Tampa, Florida. Somerset markets Eldepryl in capsule form for the treatment of patients with late-stage Parkinson's disease.
Somerset is currently engaged in the clinical development of a selegiline transdermal system for the treatment of several indications, including Alzheimer's Disease, Depression and Parkinson's Disease.
Somerset was established in 1986 and since 1988 Somerset has been jointly owned by Mylan Laboratories, Inc and Watson Pharmaceuticals, Inc.
Selegiline Hydrochloride is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl.
Each aqua blue capsule is band imprinted with the Somerset logo on the cap and Eldepryl 5 mg on the body. Each capsule contains 5 mg selegiline hydrochloride. Inactive ingredients are citric acid, lactose, magnesium stearate and microcrystalline cellulose.
The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of Parkinson's disease are not fully understood. Inhibition of monoamine oxidase, type B, activity is generally considered to be of primary importance; in addition, there is evidence that selegiline may act through other mechanisms to increase dopaminergic activity.
It is important to be aware that selegiline may have pharmacological effects unrelated to MAO B inhibition. As noted above, there is some evidence that it may increase dopaminergic activity by other mechanisms, including interfering with dopamine re-uptake at the synapse. Effects resulting from selegiline administration may also be mediated through its metabolites. Two of its three principal metabolites, amphetamine and methamphetamine, have pharmacological actions of their own. They interfere with neuronal uptake and enhance release of several neurotransmitters. However, the extent to which these metabolites contribute to the effects of selegiline are unknown.
Many of the prominent symptoms of Parkinson's disease are due to a deficiency of striatal dopamine that is the consequence of a progressive degeneration and loss of a population of dopaminergic neurons which originate in the substantia nigra of the midbrain and project to the basal ganglia or striatum. Early in the course of Parkinson's disease, the shortfall in the capacity of these neurons to synthesize dopamine can be overcome by administration of exogenous levodopa, usually given in combination with a peripheral decarboxylase inhibitor.
Back to Drug Companies
|
|
|
|
|
|
|
|